Advertisement
The new Pharmacor report entitled Chronic Obstructive Pulmonary Diseasefinds that, among the emerging combination therapies,Novartis/Schering-Plough's indacaterol/mometasone andGlaxoSmithKline/Theravance's GW-642444/GW-685698 will experience annual growthof 60 percent and 71 percent, respectively, between 2012 and 2017 as a resultof greater uptake of these once-daily, fixed-dose combination drugs. Themarket will also be driven by increased diagnosis rates in the next 10 yearsas the prevalent COPD population will rise by nearly 19 percent as a result ofaging populations in the United States, France, Germany, Italy, Spain, UnitedKingdom and Japan.
Advertisement
Although the COPD drug market in 2007 totaled just $6.6 billion, themarket has yet to realize its maximum commercial potential, according to thereport. Tapping into this great market opportunity will require significantimprovements in diagnosis as well as the availability of more effective drugtreatments, particularly therapies that address COPD-specific pathology.
"Although disease-modifying therapies are needed, treatments that providesymptomatic relief for COPD will remain the mainstay of treatment through2017," said Regina Jammen, analyst at Decision Resources. "The market willshift from monotherapy use, as well as from the use of twice-daily dosedtherapies, to combination treatments and once-daily dosed therapies as thesedrugs emerge from clinical development. Each major drug class will see theemergence of new once-daily dosed products, except for drug classes that areexclusively short-acting."
About Decision Resources
Decision Resources (http://www.decisionresources.com) is a world leader inmarket research publications, advisory services, and consulting designed tohelp clients shape strategy, allocate resources, and master their chosenmarkets.
All company, brand, or product names contained in this document may betrademarks or registered trademarks of their respective holders.For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 [email protected]
SOURCE Decision Resources, Inc.
